AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Managing Dermatologic Side Effects of Immune Checkpoint Inhibitors

Description

Anna Axelsson, a dermatologist at Henry Ford Health, discussed the management of dermatologic side effects associated with immune checkpoint inhibitors. These medications, including various inhibitors like CTLA-4 and PD-1, enhance the immune system to combat cancer but can lead to common cutaneous side effects, occurring in up to 60% of patients. The presentation outlined common dermatological reactions, highlighting maculopapular rash as the most prevalent, often managed with topical or systemic steroids. Other reactions included psoriasis-like eruptions and lichenoid dermatitis, which may necessitate advanced therapies such as biologics. The risks of severe cutaneous adverse reactions, while less frequent, were underscored, as they can be life-threatening and may require hospitalization and aggressive treatments. The presentation stressed the need for prompt management of dermatologic side effects to allow patients to continue their crucial cancer therapies. The speaker noted the importance of a multidisciplinary approach in managing these effects, advising caution with systemic immunosuppression due to its potential impact on cancer control. The implications of early immunosuppression on patient outcomes led to a call for further research to better understand these side effects and their management.

View more

Conclusions

  • Cutaneous side effects from immune checkpoint inhibitors (ICIs) are common and often present early in treatment.
  • These dermatologic toxicities can occur in up to 60% of patients, particularly in those receiving combination therapy.
  • The severity of cutaneous side effects ranges from mild to potentially severe, with approximately 5% of cases being severe.
  • Management of mild to moderate cutaneous reactions typically involves topical steroids, with systemic steroids reserved for severe cases.
  • Early identification and management of skin toxicities can potentially improve treatment outcomes and allow for continued cancer therapy.
  • The use of systemic immunosuppression should be approached cautiously due to its unknown impact on tumor control and overall patient survival.
  • Skin reactions such as SJS and TEN should be monitored closely, especially if symptoms develop after the initiation of new medications.
  • Multidisciplinary collaboration is essential for the effective management of dermatologic side effects in patients undergoing immune checkpoint therapy.
  • J Am Acad Dermatol. 2020 Nov;83(5):1255-1268.
  • Support Care Cancer. 2020 Dec;28(12):6119-6128.
  • J Am Acad Dermatol. 2022 Nov;87(5):1133-1135.
  • Arch Dermatol. 2002 Oct;138(10):1335-8.
  • JAMA Oncol. 2022 Dec 1;8(12):1794-1801.
  • Benevides L, da Fonseca DM, Donate PB, et al. IL17 Promotes Mammary Tumor Progression by Changing the Behavior of Tumor Cells and Eliciting Tumorigenic Neutrophils Recruitment. Cancer Res. 2015 Sep 15;75(18):3788-99.
  • Chen CB, Wu MY, Ng CY, et al. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Manag Res. 2018 May 17;10:1259-1273.
  • Chen CH, Yu HS, Yu S. Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article. Curr Oncol. 2022 Apr 18;29(4):2871-2886. doi: 10.3390/curroncol29040234.
  • Choi J, Anderson R, Blidner A, et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. Support Care Cancer. 2020 Dec;28(12):6119-6128. doi: 10.1007/s00520-020-05706-4.
  • Della Corte CM, Morgillo F. Early use of steroids affects immune cells and impairs immunotherapy efficacy. ESMO Open. 2019 Feb 27;4(1):e000477. doi: 10.1136/esmoopen-2018-000477.
  • Deutsch A, Lacouture M, Andriessen A, et al. INDIVIDUAL ARTICLE: USCOM Algorithm for the Prevention and Management of Cutaneous Immunotherapy-Related Adverse Events. J Drugs Dermatol. 2023 Nov.
  • Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020 Nov;83(5):1255-1268.
  • Hrin ML, Bowers NL, Jorizzo JL, et al. Tacrolimus "swish and spit" for complex aphthosis: Outcomes in 21 patients. J Am Acad Dermatol. 2022 Nov;87(5):1133-1135.
  • Ingen-Housz-Oro S, Milpied B, Badrignans M, et al. Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases. Melanoma Res. 2022 Jun 1;32(3):205-210.
  • Kuo AM, Markova A. High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer. Front Med (Lausanne). 2022 Jun 13;9:898790. doi: 10.3389/fmed.2022.898790.
  • Lacouture ME, Choi J, Ho A, et al. US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm. J Drugs Dermatol. 2021 Sep 1;20(9):3ss-s19. doi: 10.36849/jdd.6229.
  • Molina GE, Yu Z, Foreman RK, et al. Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: a multicenter case series. J Am Acad Dermatol. (2020) 83:1475-7.
  • Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R, Litvinov IV. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management. J Cutan Med Surg. 2021 Jan-Feb;25(1):59-76.
  • Olivier V, Lacour JP, Mousnier A, et al. Treatment of chronic erosive oral lichen planus with low concentrations of topical tacrolimus: an open prospective study. Arch Dermatol. 2002 Oct;138(10):1335-8.
  • Petrelli F, Signorelli D, Ghidini M, et al. Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Cancers. 2020; 12(3):546.
  • Stroud CR, Hegde A, Cherry C, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract. 2019 Apr;25(3):551-557.
  • van Not OJ, Verheijden RJ, van den Eertwegh AJM, et al. Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma. JAMA Oncol. 2022 Dec 1;8(12):1794-1801. doi: 10.1001/jamaoncol.2022.5041.